4 Stocks Boosting The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 11 points (-0.1%) at 15,227 as of Tuesday, June 11, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 560 issues advancing vs. 2,425 declining with 97 unchanged.

The Drugs industry currently sits up 0.1% versus the S&P 500, which is down 0.37. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 3.8%, Celgene Corporation ( CELG), up 1.5% and Amgen ( AMGN), up 0.5%. On the negative front, top decliners within the industry include Merck ( MRK), down 1.10, and Novartis ( NVS), down 0.47.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:

4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $2.27 (1.39) to $166.02 on average volume Thus far, 157,887 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 276,400 shares. The stock has ranged in price between $165.51-$166.78 after having opened the day at $165.84 as compared to the previous trading day's close of $163.75.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $89.6 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are down 0.2% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Questcor Pharmaceuticals ( QCOR) is up $7.52 (20.47) to $44.22 on heavy volume Thus far, 12.7 million shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $43.65-$50.20 after having opened the day at $50.00 as compared to the previous trading day's close of $36.71.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $2.2 billion and is part of the health care sector. The company has a P/E ratio of 11.3, below the S&P 500 P/E ratio of 17.7. Shares are up 35.8% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Questcor Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $0.69 (0.69) to $100.88 on light volume Thus far, 641,412 shares of Allergan exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $98.62-$101.05 after having opened the day at $99.11 as compared to the previous trading day's close of $100.19.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $29.6 billion and is part of the health care sector. The company has a P/E ratio of 26.7, above the S&P 500 P/E ratio of 17.7. Shares are up 8.7% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.22 (0.76) to $28.58 on heavy volume Thus far, 36.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 39.1 million shares. The stock has ranged in price between $27.95-$28.63 after having opened the day at $28.04 as compared to the previous trading day's close of $28.37.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $199.7 billion and is part of the health care sector. The company has a P/E ratio of 20.0, above the S&P 500 P/E ratio of 17.7. Shares are up 12.7% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE